Log in
NASDAQ:NERV

Minerva Neurosciences Stock Forecast, Price & News

$3.89
-0.12 (-2.99 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.84
Now: $3.89
$4.03
50-Day Range
$3.10
MA: $3.47
$4.01
52-Week Range
$1.81
Now: $3.89
$15.22
Volume480,771 shs
Average Volume1.33 million shs
Market Capitalization$166.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Minerva Neurosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373
Employees13

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.36 per share

Profitability

Net Income$-72,180,000.00

Miscellaneous

Market Cap$166.00 million
Next Earnings Date3/8/2021 (Estimated)
OptionableOptionable
$3.89
-0.12 (-2.99 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

How has Minerva Neurosciences' stock been impacted by Coronavirus (COVID-19)?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NERV shares have decreased by 38.8% and is now trading at $3.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Minerva Neurosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Minerva Neurosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Minerva Neurosciences?

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Minerva Neurosciences
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings data on Monday, November, 2nd. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.03.
View Minerva Neurosciences' earnings history
.

What price target have analysts set for NERV?

6 Wall Street analysts have issued twelve-month price objectives for Minerva Neurosciences' shares. Their forecasts range from $2.00 to $10.00. On average, they anticipate Minerva Neurosciences' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price.
View analysts' price targets for Minerva Neurosciences
.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,510,000 shares, a drop of 14.0% from the October 31st total of 2,920,000 shares. Based on an average daily trading volume, of 520,100 shares, the short-interest ratio is presently 4.8 days. Approximately 7.2% of the company's stock are short sold.
View Minerva Neurosciences' Short Interest
.

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 59, Pay $736.03k)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO & Chief Bus. Officer (Age 59, Pay $516.84k)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 45)
  • Mr. Frederick W. Ahlholm, Sr. VP & Chief Accounting Officer (Age 54)
  • Mr. William B. Boni, VP of Investor Relations & Corp. Communications (Age 68)
  • Mr. Devin Whittemore Smith, Sr. VP, Gen. Counsel & Sec. (Age 52)
  • Dr. Michael Davidson, Chief Medical Officer (Age 70)
  • Dr. Jay B. Saoud Ph.D., Sr. VP and Head of R&D (Age 61)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.92%), Acadian Asset Management LLC (4.00%), State Street Corp (1.43%), Sei Investments Co. (0.55%), Arrowstreet Capital Limited Partnership (0.49%) and AQR Capital Management LLC (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle.
View institutional ownership trends for Minerva Neurosciences
.

Which institutional investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, AQR Capital Management LLC, BlackRock Inc., Cubist Systematic Strategies LLC, and JPMorgan Chase & Co.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences
.

Which institutional investors are buying Minerva Neurosciences stock?

NERV stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Sei Investments Co., State Street Corp, AJO LP, ExodusPoint Capital Management LP, Sanders Morris Harris LLC, BNP Paribas Arbitrage SA, and California State Teachers Retirement System. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, Heek G Jan Van, and William F Doyle.
View insider buying and selling activity for Minerva Neurosciences
.

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.89.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $166.00 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.